Drug Profile
Research programme: gene therapies - Spark Therapeutics/University of Massachusetts Medical School
Latest Information Update: 16 May 2023
Price :
$50
*
At a glance
- Originator Spark Therapeutics
- Developer Spark Therapeutics; University of Massachusetts Medical School
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Liver disorders
- No development reported Neurological disorders; Retinal disorders
Most Recent Events
- 16 May 2023 Early research for Liver disorders is ongoing in USA (Parenteral) (Spark Therapeutics pipeline, May 2023)
- 13 Apr 2021 Spark Therapeutics and Senti Bio enter into collaboration and option agreement for the use of gene circuit technology in development of gene therapies
- 28 Nov 2020 No recent reports of development identified for research development in Liver-disorders in USA (Parenteral)